(RTTNews) - Pulse Biosciences Inc. (PLSE), in an update to its recent FDA 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System's current ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA ...

Sebaceous Hyperplasia Study Design The prospective multicenter study of the Pulse Biosciences NPS device in the treatment of SH is expected to enroll up to a total of sixty (60) patients at five ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

Please provide your email address to receive an email when new articles are posted on . Pulse Biosciences has announced it received FDA 510(k) clearance for expanding the use of its CellFX System to ...

(RTTNews) - Pulse Biosciences, Inc. (PLSE), a bioelectric medicine company, has received FDA clearance for its CellFX System to expand the indication for use in the treatment of sebaceous hyperplasia ...

(RTTNews) - Pulse Biosciences Inc.'s (PLSE) CellFX System has received Investigational Device Exemption approval from the FDA and a pivotal study evaluating this device in the treatment of sebaceous ...

This patient had sebaceous hyperplasia, a benign proliferation of the sebaceous gland that occurs in a periorbital location on patients of middle age or older. The condition is characterized by small, ...

Sebaceous hyperplasia (SH) is a common benign proliferation of sebaceous glands surrounding hair follicles. These glands are described as holocrine glands composed of acini, berry-like structures ...

Lipidio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic and dermatologic diseases, today announced the appointment of two ...